Also found in: Dictionary, Thesaurus, Wikipedia.


trademark for preparations of phenazopyridine hydrochloride; a urinary tract analgesic.

phenazopyridine hydrochloride

AZO-Gesic, Azo-Standard, Baridium, Phenazo (CA), Prodium, Pyridium, ReAzo, UTI Relief

Pharmacologic class: Nonopioid analgesic

Therapeutic class: Urinary analgesic

Pregnancy risk category B


Unknown. Thought to act locally on urinary tract mucosa to produce analgesic or anesthetic effects, relieving urinary burning, urgency, and frequency.


Tablets: 95 mg, 97.2 mg, 100 mg, 200 mg

Indications and dosages

Pain caused by lower urinary tract irritation

Adults: 200 mg P.O. t.i.d.

Children: 12 mg/kg P.O. daily in three divided doses


• Hypersensitivity to drug
• Renal insufficiency


Use cautiously in:
• hepatitis
• pregnant or breastfeeding patients
• children younger than age 12.


• Give with or after meals.
• Discontinue after 2 days, as prescribed, when administering with antibiotics.

Adverse reactions

CNS: headache

EENT: contact lens staining

GI: GI disturbances

GU: bright orange urine, renal toxicity

Hepatic: hepatotoxicity

Hematologic: hemolytic anemia,


Skin: rash, pruritus

Other: anaphylactoid-like reaction


Drug-diagnostic tests.Bilirubin, glucose, ketones, protein, steroids: interference with urine tests based on spectrophotometry or color reactions

Patient monitoring

• Monitor patient for symptomatic improvement of urinary tract infection (UTI).
• Assess follow-up urine culture after antibiotic therapy ends.

Monitor for yellowing of skin or sclera. This change may indicate drug accumulation caused by impaired renal excretion, warranting drug withdrawal.

Patient teaching

• Explain drug therapy and measures to help prevent UTI recurrence.
• Tell patient drug may discolor urine and tears and may stain clothing and contact lenses.

Advise patient to contact pre-scriber promptly if symptoms don't improve or if skin or eyes become yellow.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


A trademark for the drug phenazopyridine hydrochloride.


trademark for a urinary tract analgesic (phenazopyridine hydrochloride).


Butabarbital, see there.
References in periodicals archive ?
Pyridium (phenazopyridine hydrochloride), marketed in 1914 as a treatment for urinary tract infections (UTIs), is currently indicated as a urinary analgesic to relieve dysuric symptoms associated with UTIs, trauma, or surgery.
The patient's urologist had prescribed Pyridium tid three days earlier to treat dysuria.
The patient was initially rehydrated and the Pyridium was discontinued.
Since the first report of an adverse effect of Pyridium was published in 1951, (11) there have been very few cases involving more than a single adverse event occurring.
Although hemolytic anemia has been described as an adverse reaction to Pyridium, myelosuppressive anemia has not.
The patient's myelosuppression, acute renal failure, and skin and urine discoloration reversed upon discontinuation of the Pyridium.
Pyridium is an oral analgesic prescribed occasionally for dysuria associated with trauma, surgery and infections of the urinary tract.
Pyridium (phenazopyridine) Morris Plains, NJ: Parke-Davis, 1992.
Acquired methemoglobinemia and hemolytic anemia following excessive pyridium (phenazopyridine hydrochloride) ingestion.
Pyridium (Parke-Davis) or phenazopyridine is used as an analgesic for relief when pain, burning, urgency, frequency, and other discomforts that result from irritation of the mucosa of the lower urinary tract.